Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

The tech company estimates that its investment will create 100,000 jobs focused on AI and emerging technologies. Canal+'s shares fell on the London Stock Exchange and Havas's stock rose on Euronext ...

The biotech's candidate VK2735 belongs to the same class of drugs as Eli Lilly's star weight loss drug Zepbound -- it acts on ...

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for ...

If your heart rate increases each time you hear the word "injection," you’re not alone. Every 1 in 4 adults has a fear of ...

Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal ...